Piribo: Financial Markets Research: Endo Pharmaceuticals’ Lidoderm, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: Endo Pharmaceuticals’ Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth”. http://www.piribo.com/publications/finance_investment/financial_markets_research_endo_pharmaceuticals_lidoderm.html

Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia and a variety of off-label pain conditions with use varying by specialty.The largest barriers to use of Lidoderm are price and reimbursement but some physicians believe the situation is improving.Near-term competitive threats are not expected to substantially derail Lidoderm's growth rate.

Scope
- Understand the commercial potential for Endo Pharmaceutical's Lidoderm based on a multi-specialty physician survey
- Anticipate likely changes in the future market dynamics for pain therapies following the likely success of Lidoderm

Contents
Summary
Endo Pharmaceuticals
Lidoderm
Physician Survey Background
Use Of Lidoderm
Drivers Of Lidoderm's Growth
Lidoderm Forecast
Appendix

“Financial Markets Research: Endo Pharmaceuticals’ Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_endo_pharmaceuticals_lidoderm.html

Piribo Product ID: DAT545

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.